Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
- 1 January 1995
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 345 (8941), 9-13
- https://doi.org/10.1016/s0140-6736(95)91150-2
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Epstein-Barr virus strategy in normal and neoplastic B cellsCell, 1994
- Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative diseaseBlood, 1994
- Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1994
- Administration of Neomycin Resistance Gene Marked EBV Specific Cytotoxic T Lymphocytes to Recipients of Mismatched-Related or Phenotypically Similar Unrelated Donor Marrow Grafts. St. Jude Children's Research Hospital, Memphis, TennesseHuman Gene Therapy, 1994
- Epstein-Barr virus in lymphomas: a reviewBlood Reviews, 1993
- Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patientsThe Lancet, 1993
- Epstein-Barr Virus Infections: Biology, Pathogenesis, and ManagementAnnals of Internal Medicine, 1993
- Subtypes of Epstein-Barr virus in human immunodeficiency virus- associated non-Hodgkin lymphomaBlood, 1991
- Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.Proceedings of the National Academy of Sciences, 1989
- Geographical prevalence of two types of Epstein-Barr virusVirology, 1986